We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Introductory Chapter: The Emerging Corner of the Omics Studies for Rational Drug Design

Arli Aditya Parikesit

1. Introduction

1.1 Structural bioinformatics contributions in -omics studies

The Acceleration of COVID-19 research in Proteomics and Transcriptomics studies occurred swiftly due to the massive amount of investment and advances in biomanufacturing [1, 2]. Moreover, the repurposing drug research has elicited remdesivir as the FDA-approved drug for COVID-19, despite mixed result from the WHO solidarity trial [3]. More drug leads are also currently undergoing clinical trial as well. This rapid development in the rational drug design is strongly associated with the field of structural bioinformatics. As for now (Early December 2020), there are more than 600 deposited SARS-CoV-2 Protein structures in the PDB (per December 2020, in the <http://www.rcsb.org>). They are SARS-CoV-2 Proteins with various conformations, and bindings with various ligands [4]. Hence, those proteins structures and their annotated functions are currently subject of the extensive COVID-19 drug development along with hefty investment from the pharmaceutical companies. However, in the other side of the story, non-protein biomolecular structures are currently still off the radar. There are only handful of initiatives for the COVID-19 transcriptomics-based drugs [5–7]. However, drug-based transcriptomics initiatives in canceromics are more mature. Breast cancer transcriptomics-based leads are currently under development [8–10]. That particular progress could be elicited due to the application of structural bioinformatics method for prediction the 2D and 3D model of the nucleic acids [11]. However, massive clinical applications still in favors for the proteomics-based drugs due to the stability of the bioassay experiments. In the area of natural products computation, the only realistic approach is still the proteomics-based one. For instance, propolis, as a resinous material from bees, was a subject of intensive molecular simulation research for its respective compounds constituency as diabetes drug candidates [12]. Hence, the same material also employed for the possibility as COVID-19 leads compound [13]. Moreover, various secondary metabolite sources were also investigated as drug candidates with the molecular simulation research, such as ayurvedic plants of India, and various sources of Chinese herbal medicine [14–18]. In this regard, bioinformaticians should proceed with mindful and prudent manner on the deployment of the molecular docking method as there are validation issues that should be resolved before working on the samples [19, 20]. That includes the utilization of the docking decoys, reiterations of Tc-PLIF value, cross-docking, redocking of the attached ligand, and the refinement of the RMSD parameter [21–25]. However, the easiest validation method is the ligand redocking, provided the structure is exist in the PDB repository. The decoy deployment is the most computationally extensive of all, albeit of its high

accuracy [26]. In this end, the measurement of the computational cost should be taken into consideration when applying molecular simulation is needed [27].

2. Pharmacogenomics and personalized medicine

Although it is still in its infancy, currently there is research that investigates the tendency that certain population group will be more vulnerable to COVID-19. For instance, Population with gene pool of Neanderthals was predicted to be vulnerable considerably [28]. In Indonesia, pharmacogenomics study has elicited correlation between anti-tuberculosis drug-induced liver injury (AT-DILI) severity and NAT2 phenotypes [29]. Moreover, expression of Long non-coding RNA (lncRNA) in diabetic patient is a useful lead for the progression of the epigenetic repertoire in the human cell [30]. Then, Molecular genomic is playing important role to annotate the cardiac function analysis [31]. The 7-day regiment deployment of the malaria drug primaquine is tolerated for patient with normal level of glucose-6-phosphate dehydrogenase (G6PD). Moreover, the resistance tendency of certain population group against malaria parasite has been observed as well [32]. Cancer is one of the most extensively studied disease in the pharmacogenomics field, in the light of the intensive computational biology tools, as tendencies for prevalence were elucidated in different races [33, 34]. Thus, the progress of epigenetics research has leveraged the pharmacogenomics field with various findings of biomarkers for cancer [35]. The various progresses in the pharmacogenomics field have shown that the molecular mechanism of diseases is beginning to be uncovered accordingly, especially with the development of epigenetics marker database [36]. Bioinformatics also play important role in annotating pharmacogenomics data, especially for the development of the genomics database and the disease-outcome prediction methods [37].

3. Metabolomics and disease biomarkers

The forefront of the metabolomics research is mainly the standard instrument in the analytical biochemistry such as HPLC and GC-MS, and also some supporting organic chemistry instrumentation such as C-NMR, H-NMR, UV, and IR [28–30, 38–40]. However, the deployment of the data science approach in interpretation of the metabolomics data enables the analysis of the large data sets, and eventually the data annotation in the biological database [41, 42]. Natural products research is one of the most dynamic fronts in the metabolomics research. Herbal medicine clinical trial toward COVID-19 patients show acceptable result for patients with mild symptoms, provided that the standard therapy still apply [43–45]. Moreover, secondary metabolite could serve as disease biomarkers. Insulin-resistant individuals will have decreased serum level of glycine, and also poor biotin metabolism [46]. Currently, probiotic metabolites are undergone extensive research to determine their possible anti-SARS-CoV-2 properties [47]. Propolis studies are also focused on the metabolomics side in order to provide sufficient data to the structural bioinformatics research, especially to determine the inhibitory activities against the SARS-CoV-2 virus [48–51]. Up to today, there are still limited number of the approved natural product based drugs, such as aspirin, penicillin, and taxol [52]. Bioinformatics research has been optimized to develop a more comprehensive biological conclusion in natural product chemistry, such as the annotation of naringin role in cancer, bioactive compounds of *Zingiber officinale*,

and caffeine-aspirin interaction [53–55]. So more efforts should be elicited to improve the completeness of the natural products library, mainly to supplement the standard chemical compounds library such as Pubchem, and drug database such as drugbank. Hence, biomarkers could be elicited not only as small organic molecules, but also as larger biomolecules. For instance, the insulin level is one of the indicator of the diabetes progression, and indicator for the therapeutic options available [56]. Diabetic biomarker could be manifested as non-coding RNA as well [57, 58].

4. Medicinal chemistry and drug design in omics study

The metabolomics study is definitely inseparable from medicinal chemistry due to their overlapping domain [59]. The development of the metabolomics library enables the construction of the rich chemical-structures library, as well as their respective functional groups from the natural products [57–62]. Custom-made library will supplement the existing libraries, such as the pubchem, drugbank, and KEGG database [63–65]. In this regard, the availability of the functional-groups library will support the fragment-based drug design, where specialized algorithm was devised to inhibit every corner of the protein's cavity [66, 67]. Hence, the main challenge of this approach will be in the medicinal chemistry perspective, when extrapolating the in silico research into the in vitro one become necessary. Synthesizing custom-made compounds from fragment library will not be straightforward due to the special reaction condition needed, the existence of the new structural backbone, and the availability of the chemical reagents [68]. In this end, the current standing of the medicinal chemistry field is still depend upon the derivatization of the current structural library of compounds, in order to develop new lead with feasible reaction conditions [69]. Metabolomics plays dominant role in developing such library. One of the application of this particular approach is the development of ceftaroline, which is a fifth-generation broad-spectrum cephalosporin antibiotic [70].

5. Outlook

Parallelization in the Drug Biomanufacturing with incremental optimization will facilitate the pipeline of therapeutic agent development [71, 72]. Such biomanufacturing efforts will be enhanced with the implementation of Artificial Intelligence (AI) for massive drug screening that could be beneficial for multi-components drug lead such as herbal medication, and machine-learning based implementation for such pipelines has been devised accordingly in COVID-19 leads development [73–76]. The extensive utilization of the common data science methods in bioinformatics, such as machine learning, will eventually provide insight that the management of life sciences data requires more than just becoming application users [77]. Massive automation efforts in the field of life sciences will eventually push forward with the inevitable integration with formal sciences, namely with both computer science and data science [78]. In this end, Bioinformatics will play important role to manage the experimental data from the life sciences lab [79]. For instance, utilization of the SUPERFAMILY and Gene Ontology database for annotating the protein domain expression of the *Plasmodium sp.* parasite could be a doable venue [80, 81]. Thus, the promises that already delivered by the omics studies will eventually shed light to the current state of the COVID-19 pandemic (per December 2020), and could elicit various therapeutic options for many more

infectious diseases. However, non-communicable disease such as various types of cancer and diabetes will remain a challenging task to resolve as they invoke deep understanding of the human immunological system. It involves the utilization of the immunoinformatics tools that proceed beyond this chapter [82, 83]. Hence, it should be reminded that the basic sciences behind the omics studies could not be overlooked. Medicinal chemistry, biochemistry, molecular biology, biomedicine and biotechnology will remain important, as well as emerging sciences such as bioinformatics and data sciences.

Acknowledgements

The authors would like to thank the Institute for Research and Community Services (LPPM) of Indonesia International Institute for Life Sciences (I3L) for their heartfelt support. Thanks also go to the Indonesian Society for Bioinformatics and Biodiversity (ISBB) or *Masyarakat Bioinformatika dan Biodiversitas Indonesia* (MABBI) members and leaders for the thorough forum group discussion on the topic of COVID-19 pandemic, artificial intelligence for drug design, and molecular docking validation.

Author details

Arli Aditya Parikesit

Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jl. Pulomas Barat Kav.88, Jakarta, 13210, Indonesia

*Address all correspondence to: arli.parikesit@i3l.ac.id

IntechOpen

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] J.H. Martin, N.A. Bowden, Drug repurposing in the era of COVID-19: a call for leadership and government investment, *Med. J. Aust.* 212 (2020) 450-452.e1. <https://doi.org/10.5694/mja2.50603>.
- [2] D.J. Payne, L.F. Miller, D. Findlay, J. Anderson, L. Marks, Time for a change: addressing R&D and commercialization challenges for antibacterials, *Philos. Trans. R. Soc. B Biol. Sci.* 370 (2015) 20140086. <https://doi.org/10.1098/rstb.2014.0086>.
- [3] M. Gadebusch Bondio, M. Marloth, The “Historic Study” SOLIDARITY—Research’s Answer to the Sars-CoV-2 Pandemic, *NTM Int. J. Hist. Ethics Nat. Sci. Technol. Med.* (2020). <https://doi.org/10.1007/s00048-020-00257-5>.
- [4] F.K. Yoshimoto, The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19, *Protein J.* 39 (2020) 198-216. <https://doi.org/10.1007/s10930-020-09901-4>.
- [5] A.A. Parikesit, R. Nurdiansyah, The Predicted Structure for the Anti-Sense siRNA of the RNA Polymerase Enzyme (RdRp) gene of the SARS-CoV-2, *Ber. Biol.* 19 (2020) 97-108. <https://doi.org/10.14203/beritabiologi.v19i1.3849>.
- [6] H. Uludağ, K. Parent, H.M. Aliabadi, A. Haddadi, Prospects for RNAi Therapy of COVID-19, *Front. Bioeng. Biotechnol.* (2020). <https://doi.org/10.3389/fbioe.2020.00916>.
- [7] K. Lundstrom, Viral vectors applied for RNAi-based antiviral therapy, *Viruses.* (2020). <https://doi.org/10.3390/v12090924>.
- [8] J. Ivan, R. Nurdiansyah, A.A. Parikesit, Computational modeling of AGO-mediated molecular inhibition of ARF6 by miR-145, *Indones. J. Biotechnol.* 25 (2020). <https://doi.org/10.22146/ijbiotech.55631>.
- [9] P.J. Kaboli, A. Rahmat, P. Ismail, K.-H. Ling, MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment., *Pharmacol. Res.* 97 (2015) 104-121. <https://doi.org/10.1016/j.phrs.2015.04.015>.
- [10] M. Fan, R. Krutilina, J. Sun, A. Sethuraman, C.H. Yang, Z.-H. Wu, J. Yue, L.M. Pfeffer, Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells., *J. Biol. Chem.* 288 (2013) 27480-27493. <https://doi.org/10.1074/jbc.M113.491803>.
- [11] R. Wijaya, A.A. Parikesit, R. Nurdiansyah, 3D And 2D RNA Structure Prediction Of The BRCA2 Gene And Its Silencing RNA In The Breast Cancer, *Walisongo J. Chem.* 3 (2020) 10. <https://doi.org/10.21580/wjc.v3i1.6019>.
- [12] M. Sahlan, M.N.H. Al Faris, R. Aditama, K. Lischer, A.C. Khayrani, D.K. Pratami, Molecular Docking of South Sulawesi Propolis against Fructose 1,6-Bisphosphatase as a Type 2 Diabetes Mellitus Drug, *Int. J. Technol.* 11 (2020) 910. <https://doi.org/10.14716/ijtech.v11i5.4332>.
- [13] M. Sahlan, R. Irdiani, D. Flamandita, R. Aditama, S. Alfarraj, M.J. Ansari, A.C. Khayrani, D.K. Pratami, K. Lischer, Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery., *J. King Saud Univ. Sci.* 33 (2021) 101234. <https://doi.org/10.1016/j.jksus.2020.101234>.
- [14] A.J. Gandhi, J.D. Rupareliya, V.J. Shukla, S.B. Donga, R. Acharya, An ayurvedic perspective along

with in silico study of the drugs for the management of SARS-CoV-2, *J. Ayurveda Integr. Med.* (2020). <https://doi.org/10.1016/j.jaim.2020.07.002>.

[15] M. Amaravani, N.K. Prasad, V. Ramakrishna, COX-2 structural analysis and docking studies with gallic acid structural analogues, *Springerplus.* (2012). <https://doi.org/10.1186/2193-1801-1-58>.

[16] R. V. Chikhale, S.K. Sinha, R.B. Patil, S.K. Prasad, A. Shakya, N. Gurav, R. Prasad, S.R. Dhaswadikar, M. Wanjari, S.S. Gurav, In-silico investigation of phytochemicals from *Asparagus racemosus* as plausible antiviral agent in COVID-19, *J. Biomol. Struct. Dyn.* (2020). <https://doi.org/10.1080/07391102.2020.1784289>.

[17] D. Zhang, K. Wu, X. Zhang, S. Deng, B. Peng, In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus, *J. Integr. Med.* 18 (2020) 152-158. <https://doi.org/10.1016/j.joim.2020.02.005>.

[18] A.A. Parikesit, R. Nurdiansyah, D. Agustriawan, Telaah Sistematis Terhadap Basis Data Bahan Alam untuk Pengembangan Produk Suplemen Herbal, *Pros. SEMNASTAN.* 0 (2018) 62-68. <https://jurnal.umj.ac.id/index.php/semnastan/article/view/2259/1874> (accessed January 28, 2018).

[19] K.E. Hevener, W. Zhao, D.M. Ball, K. Babaoglu, J. Qi, S.W. White, R.E. Lee, Validation of molecular docking programs for virtual screening against dihydropteroate synthase, *J. Chem. Inf. Model.* 49 (2009) 444-460. <https://doi.org/10.1021/ci800293n>.

[20] D.T. Moustakas, P.T. Lang, S. Pegg, E. Pettersen, I.D. Kuntz, N. Brooijmans, R.C. Rizzo, Development and validation of a modular, extensible docking program: DOCK 5, *J. Comput.*

Aided. Mol. Des. (2006). <https://doi.org/10.1007/s10822-006-9060-4>.

[21] A. Setiawati, F.D.O. Riswanto, S.H. Yuliani, E.P. Istyastono, Retrospective Validation of a Structure-Based Virtual Screening Protocol to Identify Ligands for Estrogen Receptor Alpha and Its Application to Identify the Alpha-Mangostin Binding Pose, *Indones. J. Chem.* 14 (2014) 103-108. <https://doi.org/10.22146/ijc.21245>.

[22] E.P. Istyastono, F.D.O. Riswanto, S.H. Yuliani, Computer-Aided Drug Repurposing: A Cyclooxygenase-2 Inhibitor Celecoxib as a Ligand for Estrogen Receptor Alpha, *Indones. J. Chem.* 15 (2015) 274-280. <https://doi.org/10.22146/ijc.21196>.

[23] A. Radwan, G.M. Mahrous, Docking studies and molecular dynamics simulations of the binding characteristics of waldiomycin and its methyl ester analog to *Staphylococcus aureus* histidine kinase, *PLoS One.* 15 (2020) e0234215. <https://doi.org/10.1371/journal.pone.0234215>.

[24] J. Shamsara, CrossDock: a tool for performing cross-docking using Autodock Vina, *Springerplus.* 5 (2016) 344. <https://doi.org/10.1186/s40064-016-1972-4>.

[25] Z. Ibrahim, B.A. Tejo, M.A.M. Latif, R.A. Karjiban, A.B. Salleh, M.B.A. Rahman, In-silico Identification of Potential Protein Arginine Deiminase IV (PAD4) Inhibitors, *Malaysian J. Anal. Sci.* 20 (2016) 1269-1277. <https://doi.org/10.17576/mjas-2016-2006-05>.

[26] M.M. Mysinger, M. Carchia, J.J. Irwin, B.K. Shoichet, Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking, *J. Med. Chem.* 55 (2012) 6582-6594. <https://doi.org/10.1021/jm300687e>.

- [27] T. Liu, D. Lu, H. Zhang, M. Zheng, H. Yang, Y. Xu, C. Luo, W. Zhu, K. Yu, H. Jiang, Applying high-performance computing in drug discovery and molecular simulation, *Natl. Sci. Rev.* 3 (2016) 49-63. <https://doi.org/10.1093/nsr/nww003>.
- [28] H. Zeberg, S. Pääbo, The major genetic risk factor for severe COVID-19 is inherited from Neanderthals, *Nature*. 587 (2020) 610-612. <https://doi.org/10.1038/s41586-020-2818-3>.
- [29] R. Yuliwulandari, K. Prayuni, R.W. Susilowati, S. Subagyo, S. Soedarsono, A.S. M Sofro, K. Tokunaga, J.G. Shin, NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in Indonesian population, *Pharmacogenomics*. 20 (2019) 1303-1310. <https://doi.org/10.2217/pgs-2019-0131>.
- [30] M. Fachrul, D.H. Utomo, A.A. Parikesit, lncRNA-based study of epigenetic regulations in diabetic peripheral neuropathy., *Silico Pharmacol.* 6 (2018) 7. <https://doi.org/10.1007/s40203-018-0042-8>.
- [31] A. Pasipoularides, Genomic translational research: Paving the way to individualized cardiac functional analyses and personalized cardiology, *Int. J. Cardiol.* 230 (2017) 384-401. <https://doi.org/10.1016/j.ijcard.2016.12.097>.
- [32] S.H. Keenihan, R. Gramzinski, S. Ratiwayanto, H. Hadiputranto, W. Riberu, S. Soebianto, F. Rusjdy, D. Syafruddin, A. Kartikasari, M. Djojosebroto, I. Setianingsih, A. Harahap, Krisin, D. Fryauff, T. Richie, Y. Charoenvit, H.A. Marwoto, S. Kumar, S. Hoffman, S. Marzuki, K. Baird, *Plasmodium falciparum*: Mechanisms of innate and acquired protection against *Plasmodium falciparum* in Javanese transmigrant adults and children newly resident in malaria-endemic Northwest Papua, in: *Adv. Exp. Med. Biol.*, Kluwer Academic/Plenum Publishers, 2003: pp. 83-102. https://doi.org/10.1007/978-1-4615-0059-9_7.
- [33] S. Bernard, D. Agustriawan, Identification of microRNA targeting cancer gene of colorectal carcinoma in Caucasian population, in: 2019 Int. Conf. Inf. Commun. Technol. ICOIACT 2019, Institute of Electrical and Electronics Engineers Inc., 2019: pp. 423-427. <https://doi.org/10.1109/ICOIACT46704.2019.8938488>.
- [34] M.Z. Arifin N, D. Agustriawan, A.A. Parikesit, R. Nurdiansyah, K.N. Ramanto, Identification of microRNAs targeting NAT1 and NAT2 gene transcripts in prostate cancer patients observed in different races, *IOP Conf. Ser. Mater. Sci. Eng.* 546 (2019) 062017. <https://doi.org/10.1088/1757-899X/546/6/062017>.
- [35] D. Agustriawan, C.H. Huang, J.J.C. Sheu, S.C. Lee, J.J.P. Tsai, N. Kurubanjerdjit, K.L. Ng, DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis, *Comput. Biol. Chem.* (2016). <https://doi.org/10.1016/j.compbiolchem.2016.09.016>.
- [36] D. Agustriawan, E.B. Wijaya, C.-H. Huang, E. Lim, I.-C. Hsueh, K.-R. Tzeng, K.-L. Ng, MethmiRbase : a Database of DNA Methylation and miRNA Expression in Human Cancer, *Lect. Notes Eng. Comput. Sci. I* (2016) 16-19.
- [37] C.F. Thorn, T.E. Klein, R.B. Altman, Pharmacogenomics and bioinformatics: PharmGKB, *Pharmacogenomics*. 11 (2010) 501-505. <https://doi.org/10.2217/pgs.10.15>.
- [38] M.D. Luque de Castro, F. Priego-Capote, The analytical process to search for metabolomics biomarkers,

- J. Pharm. Biomed. Anal. 147 (2018) 341-349. <https://doi.org/10.1016/j.jpba.2017.06.073>.
- [39] Q. Li, C. Zhao, Y. Zhang, H. Du, T. Xu, X. Xu, J. Zhang, T. Kuang, X. Lai, G. Fan, Y. Zhang, 1H NMR-Based Metabolomics Coupled With Molecular Docking Reveal the Anti-Diabetic Effects and Potential Active Components of *Berberis verna* on Type 2 Diabetic Rats, *Front. Pharmacol.* 11 (2020) 932. <https://doi.org/10.3389/fphar.2020.00932>.
- [40] D.C. Tan, N.K. Kassim, I.S. Ismail, M. Hamid, M.S. Ahamad Bustamam, Identification of antidiabetic metabolites from *paederia foetida* l. Twigs by gas chromatography-mass spectrometry-based metabolomics and molecular docking study, *Biomed Res. Int.* 2019 (2019). <https://doi.org/10.1155/2019/7603125>.
- [41] F.C.P. Navarro, H. Mohsen, C. Yan, S. Li, M. Gu, W. Meyerson, M. Gerstein, Genomics and data science: An application within an umbrella, *Genome Biol.* 20 (2019) 109. <https://doi.org/10.1186/s13059-019-1724-1>.
- [42] J. Godzien, A. Gil de la Fuente, A. Otero, C. Barbas, Metabolite Annotation and Identification, in: *Compr. Anal. Chem.*, Elsevier B.V., 2018: pp. 415-445. <https://doi.org/10.1016/bs.coac.2018.07.004>.
- [43] L. Ang, E. Song, H.W. Lee, M.S. Lee, Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials, *J. Clin. Med.* 9 (2020) 1583. <https://doi.org/10.3390/jcm9051583>.
- [44] X. Luo, X. Ni, J. Lin, Y. Zhang, L. Wu, D. Huang, Y. Liu, J. Guo, W. Wen, Y. Cai, Y. Chen, L. Lin, The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis, *Phytomedicine.* (2020) 153282. <https://doi.org/10.1016/j.phymed.2020.153282>.
- [45] W. Pang, Z. Liu, N. Li, Y. Li, F. Yang, B. Pang, X. Jin, W. Zheng, J. Zhang, Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis, *Integr. Med. Res.* 9 (2020) 100477. <https://doi.org/10.1016/j.imr.2020.100477>.
- [46] S. Vaishya, R.D. Sarwade, V. Seshadri, MicroRNA, proteins, and metabolites as novel biomarkers for prediabetes, diabetes, and related complications, *Front. Endocrinol. (Lausanne).* 9 (2018). <https://doi.org/10.3389/fendo.2018.00180>.
- [47] F. Anwar, H.N. Altayb, F.A. Al-Abbasi, A.L. Al-Malki, M.A. Kamal, V. Kumar, Antiviral effects of probiotic metabolites on COVID-19., *J. Biomol. Struct. Dyn.* (2020) 1-10. <https://doi.org/10.1080/07391102.2020.1775123>.
- [48] H. Refaat, F.M. Mady, H.A. Sarhan, H.S. Rateb, E. Alaaeldin, Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19, *Int. J. Pharm.* (2020). <https://doi.org/10.1016/j.ijpharm.2020.120028>.
- [49] C.A. Scorza, V.C. Gonçalves, F.A. Scorza, A.C. Fiorini, A.C.G. de Almeida, M.C.M. Fonseca, J. Finsterer, Propolis and coronavirus disease 2019 (COVID-19): Lessons from nature, *Complement. Ther. Clin. Pract.* 41 (2020) 101227. <https://doi.org/10.1016/j.ctcp.2020.101227>.
- [50] A.A. Berretta, M.A.D. Silveira, J.M. Córdor Capcha, D. De Jong, Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19, *Biomed. Pharmacother.* 131 (2020) 110622. <https://doi.org/10.1016/j.biopha.2020.110622>.

- [51] H.I. Güler, G. Tatar, O. Yildiz, A.O. Belduz, ..., An investigation of ethanolic propolis extracts: Their potential inhibitor properties against ACE-II receptors for COVID-19 treatment by Molecular Docking Study, Sci. (2020).
- [52] A. Amit Koparde, R. Chandrashekar Doijad, C. Shripal Magdum, Natural Products in Drug Discovery, in: Pharmacogn. - Med. Plants, IntechOpen, 2019. <https://doi.org/10.5772/intechopen.82860>.
- [53] A. Fadholly, A.N.M. Ansori, T.H. Sucipto, An overview of naringin: Potential anticancer compound of citrus fruits, Res. J. Pharm. Technol. 13 (2020) 5613-5619. <https://doi.org/10.5958/0974-360X.2020.00979.8>.
- [54] W.E. Putra, V.D. Kharisma, H. Susanto, Potential of *Zingiber officinale* bioactive compounds as inhibitory agent against the IKK-B, in: AIP Conf. Proc., American Institute of Physics Inc., 2020: p. 040048. <https://doi.org/10.1063/5.0002478>.
- [55] V. Dhea Kharisma, A. Nur, M. Ansori, A. Fadholly, T.H. Sucipto, Molecular Mechanism of Caffeine-Aspirin Interaction in Kopi Balur 1 as Anti-Inflammatory Agent: A Computational Study, 2020. <https://doi.org/10.37506/IJFMTV14I4.12274>.
- [56] World Health Organization, Global Report on Diabetes, Isbn. 978 (2016) 88. <https://doi.org/ISBN 978 92 4 156525 7>.
- [57] C. Guay, R. Regazzi, Circulating microRNAs as novel biomarkers for diabetes mellitus, Nat. Rev. Endocrinol. 9 (2013) 513-521. <https://doi.org/10.1038/nrendo.2013.86>.
- [58] E. Guarino, C.D. Poggi, G.E. Grieco, V. Cenci, E. Ceccarelli, I. Crisci, G. Sebastiani, F. Dotta, Circulating MicroRNAs as biomarkers of gestational diabetes mellitus: Updates and perspectives, Int. J. Endocrinol. 2018 (2018). <https://doi.org/10.1155/2018/6380463>.
- [59] M. Frédérich, B. Pirotte, M. Fillet, P. De Tullio, Metabolomics as a Challenging Approach for Medicinal Chemistry and Personalized Medicine, J. Med. Chem. 59 (2016) 8649-8666. <https://doi.org/10.1021/acs.jmedchem.5b01335>.
- [60] L. Li, R. Li, J. Zhou, A. Zuniga, A.E. Stanislaus, Y. Wu, T. Huan, J. Zheng, Y. Shi, D.S. Wishart, G. Lin, MyCompoundID: Using an evidence-based metabolome library for metabolite identification, Anal. Chem. 85 (2013) 3401-3408. <https://doi.org/10.1021/ac400099b>.
- [61] A. Yanuar, A. Mun'im, A.B.A. Lagho, R.R. Syahdi, M. Rahmat, H. Suhartanto, Medicinal Plants Database and Three Dimensional Structure of the Chemical Compounds from Medicinal Plants in Indonesia, Int. J. Comput. Sci. 8 (2011) 180-183. <http://arxiv.org/abs/1111.7183> (accessed March 23, 2014).
- [62] A.A. Parikesit, B. Ardiansah, D.M. Handayani, U.S.F. Tambunan, D. Kerami, Virtual screening of Indonesian flavonoid as neuraminidase inhibitor of influenza a subtype H5N1, IOP Conf. Ser. Mater. Sci. Eng. 107 (2016) 012053. <https://doi.org/10.1088/1757-899X/107/1/012053>.
- [63] D.S. Wishart, C. Knox, A.C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, J. Woolsey, DrugBank: a comprehensive resource for in silico drug discovery and exploration., Nucleic Acids Res. 34 (2006) D668-D672.
- [64] S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, J. Wang, B. Yu, J. Zhang, S.H. Bryant, PubChem substance and compound databases,

- Nucleic Acids Res. 44 (2016) D1202–D1213. <https://doi.org/10.1093/nar/gkv951>.
- [65] M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, K. Morishima, KEGG: New perspectives on genomes, pathways, diseases and drugs, *Nucleic Acids Res.* 45 (2017) D353–D361. <https://doi.org/10.1093/nar/gkw1092>.
- [66] T. Wang, M.-B. Wu, Z.-J. Chen, H. Chen, J.-P. Lin, L.-R. Yang, Fragment-based drug discovery and molecular docking in drug design., *Curr. Pharm. Biotechnol.* 16 (2015) 11-25. <http://www.ncbi.nlm.nih.gov/pubmed/25420726> (accessed February 24, 2015).
- [67] Y. Chen, D.T. Pohlhaus, In silico docking and scoring of fragments., *Drug Discov. Today. Technol.* 7 (2010) e147–e202. <https://doi.org/10.1016/j.ddtec.2010.11.002>.
- [68] D. Seebach, Organic Synthesis—Where now?, *Angew. Chemie Int. Ed. English.* 29 (1990) 1320-1367. <https://doi.org/10.1002/anie.199013201>.
- [69] R. Liu, X. Li, K.S. Lam, Combinatorial chemistry in drug discovery, *Curr. Opin. Chem. Biol.* 38 (2017) 117-126. <https://doi.org/10.1016/j.cbpa.2017.03.017>.
- [70] H. Zhang, Y. Xu, P. Jia, Y. Zhu, G. Zhang, J. Zhang, S. Duan, W. Kang, T. Wang, R. Jing, J. Cheng, Y. Liu, Q. Yang, Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012-2016), *Antimicrob. Resist. Infect. Control.* 9 (2020) 166. <https://doi.org/10.1186/s13756-020-00829-z>.
- [71] C.L. Gargalo, I. Udugama, K. Pontius, P.C. Lopez, R.F. Nielsen, A. Hasanzadeh, S.S. Mansouri, C. Bayer, H. Junicke, K. V. Gernaey, Towards smart biomanufacturing: a perspective on recent developments in industrial measurement and monitoring technologies for bio-based production processes, *J. Ind. Microbiol. Biotechnol.* 47 (2020) 947-964. <https://doi.org/10.1007/s10295-020-02308-1>.
- [72] A. Boulila, M. Ayadi, S. Marzouki, S. Bouzidi, Contribution to a biomedical component production using incremental sheet forming, *Int. J. Adv. Manuf. Technol.* 95 (2018) 2821-2833. <https://doi.org/10.1007/s00170-017-1397-4>.
- [73] M.F.A.-H. Ginoga, R. Trisminingsih, W.A. Kusuma, Drug-Target Visualization on IJAH Analytics Using Sankey Diagram, in: 2020 Int. Conf. Comput. Sci. Its Appl. Agric., IEEE, 2020: pp. 1-6. <https://doi.org/10.1109/ICOSICA49951.2020.9243285>.
- [74] A. Reinaldo, W.A. Kusuma, H. Rahmawan, Y. Herdiyeni, Implementation of Breadth-First Search Parallel to Predict Drug-Target Interaction in Plant-Disease Graph, in: 2020 Int. Conf. Comput. Sci. Its Appl. Agric., IEEE, 2020: pp. 1-5. <https://doi.org/10.1109/ICOSICA49951.2020.9243216>.
- [75] D. Afdhal, K.W. Ananta, W.S. Hartono, Adverse Drug Reactions Prediction Using Multi-label Linear Discriminant Analysis and Multi-label Learning, 2020 Int. Conf. Adv. Comput. Sci. Inf. Syst. (2020) 69-76. <https://doi.org/10.1109/ICACIS51025.2020.9263166>.
- [76] F. Sulistiawan, W.A. Kusuma, N.S. Ramadhanti, A. Tedjo, Drug-Target Interaction Prediction in Coronavirus Disease 2019 Case Using Deep Semi-Supervised Learning Model, in: 2020 Int. Conf. Adv. Comput. Sci. Inf. Syst., IEEE, 2020: pp. 83-88. <https://doi.org/10.1109/ICACIS51025.2020.9263241>.

[77] S. Dash, S.K. Shakyawar, M. Sharma, S. Kaushik, Big data in healthcare: management, analysis and future prospects, *J. Big Data*. 6 (2019) 1-25. <https://doi.org/10.1186/s40537-019-0217-0>.

[78] D. Besozzi, L. Manzoni, M.S. Nobile, S. Spolaor, M. Castelli, L. Vanneschi, P. Cazzaniga, S. Ruberto, L. Rundo, A. Tangherloni, Computational Intelligence for Life Sciences, *Fundam. Informaticae*. 171 (2019) 57-80. <https://doi.org/10.3233/FI-2020-1872>.

[79] A.A. PARIKESIT, D. ANUROGO, R.A. PUTRANTO, Pemanfaatan bioinformatika dalam bidang pertanian dan kesehatan (The utilization of bioinformatics in the field of agriculture and health), *E-Journal Menara Perkeb.* 85 (2017). <https://doi.org/10.22302/iribb.jur.mp.v85i2.237>.

[80] F.H. Hasanah, E. Sulistyaningsih, W.D. Sawitri, The Expression of The PfEMP1-DBL2 β Recombinant Protein of Plasmodium falciparum Welch, 1897 Isolated From Indonesia, *J. ILMU DASAR*. 21 (2020) 67. <https://doi.org/10.19184/jid.v21i1.10494>.

[81] A.A. Parikesit, D.H. Utomo, N. Karimah, Protein Domain Annotation of Plasmodium spp. Circumsporozoite Protein (CSP) Using Hidden Markov Model-based Tools, *J. Biol. Indones.* 14 (2018) 185-190. <https://doi.org/10.14203/jbi.v14i2.3737>.

[82] N. Tomar, R.K. De, Immunoinformatics: an integrated scenario, *Immunology*. 131 (2010) 153-168. <https://doi.org/10.1111/j.1365-2567.2010.03330.x>.

[83] D.R. Flower, Immunoinformatics: Predicting Immunogenicity in Silico, Humana, 2007. <http://books.google.co.id/books?id=IJtZurJ5BvoC>.